Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-ε-caprolactone based nanoparticles

International Journal of Pharmaceutics

Volumn 504, Issue 1-2, 2016, Pages 59-69

  Jesus, Sandra ^a,b   Soares, Edna ^a,b   Costa, João ^a   Borchard, Gerrit ^c   Borges, Olga ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Antigen delivery; Dose response; Mucosal immunization; nanoparticles; Poly e caprolactone (PCL) chitosan; Polymeric biomaterials; Vaccine adjuvants

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; POLYCAPROLACTONE; CHITOSAN; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; MUCIN; NANOPARTICLE; POLYESTER;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG FORMULATION; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; MOUSE; MUCOSAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT MUCOSA; SURFACE CHARGE; VACCINATION; ZETA POTENTIAL; ANIMAL; BLOOD; C57BL MOUSE; CACO-2 CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FEMALE; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MUCOSA; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADSORPTION; ANIMALS; CACO-2 CELLS; CELL LINE, TUMOR; CELL SURVIVAL; CHITOSAN; FEMALE; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE, INBRED C57BL; MUCINS; MUCOUS MEMBRANE; NANOPARTICLES; POLYESTERS; VACCINATION;

EID: 84961918592     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.03.013     Document Type: Article

References (47)

1. D. Bento, H.F. Staats, and O. Borges Effect of particulate adjuvant on the anthrax protective antigen Dose required for effective nasal vaccination Vaccine 2015
2. G. Borchard, M.L. Cassara, P.E. Roemele, B.I. Florea, and H.E. Junginger Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3) J. Pharm. Sci. 91 2002 1561 1567
3. O. Borges, G. Borchard, J.C. Verhoef, A. de Sousa, and H.E. Junginger Preparation of coated nanoparticles for a new mucosal vaccine delivery system Int. J. Pharm. 299 2005 155 166
4. O. Borges, G. Borchard, A. de Sousa, H.E. Junginger, and A. Cordeiro-da-Silva Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers Int. J. Pharm. 337 2007 254 264
5. O. Borges, F. Lebre, D. Bento, G. Borchard, and H.E. Junginger Mucosal vaccines: Recent progress in understanding the natural barriers Pharm. Res. 27 2010 211 223
6. L.H. Chuah, N. Billa, C.J. Roberts, J.C. Burley, and S. Manickam Curcumin-containing chitosan nanoparticles as a potential mucoadhesive delivery system to the colon Pharm. Dev. Technol. 18 2013 591 599
7. A.G. Coombes, E.C. Lavelle, P.G. Jenkins, and S.S. Davis Single Dose, polymeric, microparticle-based vaccines: The influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen Vaccine 14 1996 1429 1438
8. J. De Souza Reboucas, I. Esparza, M. Ferrer, M.L. Sanz, J.M. Irache, and C. Gamazo Nanoparticulate adjuvants and delivery systems for allergen immunotherapy J. Biomed. Biotechnol. 2012 2012 474605
9. S. Dhawan, A.K. Singla, and V.R. Sinha Evaluation of mucoadhesive properties of chitosan microspheres prepared by different methods AAPS PharmSciTech 5 2004 e67
10. L.M. Ensign, R. Cone, and J. Hanes Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers Adv. Drug Deliv. Rev. 64 2012 557 570
11. J.E. Eyles, I.D. Spiers, E.D. Williamson, and H.O. Alpar Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines Vaccine 16 1998 2000 2009
12. S. Ferruzza, C. Rossi, M.L. Scarino, and Y. Sambuy A protocol for differentiation of human intestinal Caco-2 cells in asymmetric serum-containing medium Toxicol. In Vitro 26 2012 1252 1255
13. B.I. Florea, M.L. Cassara, H.E. Junginger, and G. Borchard Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3 Journal of Control. Release 87 2003 131 138
14. H.F. Florindo, S. Pandit, L. Lacerda, L.M. Goncalves, H.O. Alpar, and A.J. Almeida The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone-based nanoparticles Biomaterials 30 2009 879 891
15. K. Gerloff, D.I. Pereira, N. Faria, A.W. Boots, J. Kolling, I. Forster, C. Albrecht, J.J. Powell, and R.P. Schins Influence of simulated gastrointestinal conditions on particle-induced cytotoxicity and interleukin-8 regulation in differentiated and undifferentiated Caco-2 cells Nanotoxicology 7 2013 353 366
16. N.K. Gupta, P. Tomar, V. Sharma, and V.K. Dixit Development and characterization of chitosan coated poly-(varepsilon-caprolactone) nanoparticulate system for effective immunization against influenza Vaccine 29 2011 9026 9037
17. M. Haghi, P.M. Young, D. Traini, R. Jaiswal, J. Gong, and M. Bebawy Time- A nd passage-dependent characteristics of a Calu-3 respiratory epithelial cell model Drug Dev. Ind. Pharm. 36 2010 1207 1214
18. J. Holmgren, and C. Czerkinsky Mucosal immunity and vaccines Nat. Med. 11 2005 S45 53
19. S. Jesus, G. Borchard, and O. Borges Effect of the inclusion of chitosan into poly-Epsilon-Caprolactone particles on adsorption efficacy of 4 different model antigens J. Eur. J. Pharm. Sci. 32 2011 135 136 (4th bbbb-bled international conference on pharmaceutical sciences - new trends in drug discovery, delivery systems and laboratory diagnostics)
20. S. Jesus, G. Borchard, and O. Borges Freeze dried chitosan/Poly-e-Caprolactone and poly-e-Caprolactone nanoparticles: Evaluation of their potential as DNA and antigen delivery systems J. Genet. Syndr. Gene Ther. 4 2013
21. M.E. Kreft, U.D. Jerman, E. Lasic, T. Lanisnik Rizner, N. Hevir-Kene, L. Peternel, and K. Kristan The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model Pharm. Res. 32 2015 665 679
22. G. Leslie Flow Cytometry - A Basic Guide 2006 Institute of Medical Biology, University of Southern Denmark
23. J.H. MacLachlan, and B.C. Cowie Hepatitis B virus epidemiology Cold Spring Harbor Perspect. Med. 5 2015
24. M. Mantle, and A. Allen A colorimetric assay for glycoproteins based on the periodic acid/Schiff stain [proceedings] Biochem. Soc. Trans. 6 1978 607 609
25. A. Martinac, J. Filipovic-Grcic, D. Voinovich, B. Perissutti, and E. Franceschinis Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery Int. J. Pharm. 291 2005 69 77
26. L. Mazzarino, L. Coche-Guerente, P. Labbe, E. Lemos-Senna, and R. Borsali On the mucoadhesive properties of chitosan-coated polycaprolactone nanoparticles loaded with curcumin using quartz crystal microbalance with dissipation monitoring J. Biomed. Nanotechnol. 10 2014 787 794
27. M.R. Neutra, and P.A. Kozlowski Mucosal vaccines: The promise and the challenge. Nature reviews Immunology 6 2006 148 158
28. P.L. Ogra, H. Faden, and R.C. Welliver Vaccination strategies for mucosal immune responses Clin. Microbiol. Rev. 14 2001 430 445
29. S. Patil, A. Babbar, R. Mathur, A. Mishra, and K. Sawant Mucoadhesive chitosan microspheres of carvedilol for nasal administration J. Drug Target. 18 2010 321 331
30. D. Pawar, and K.S. Jaganathan Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: Enhancement of mucosal and systemic immune response Drug Deliv. 2014 1 11
31. D. Pawar, A.K. Goyal, S. Mangal, N. Mishra, B. Vaidya, S. Tiwari, A.K. Jain, and S.P. Vyas Evaluation of mucoadhesive PLGA microparticles for nasal immunization AAPS J. 12 2010 130 137
32. D. Pawar, S. Mangal, R. Goswami, and K.S. Jaganathan Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: Effect of mucoadhesive coating on antigen uptake and immune adjuvant activity Eur. J. Pharm. Biopharm. 85 2013 550 559
33. N. Petrovsky, and J.C. Aguilar Vaccine adjuvants: Current state and future trends Immunol. Cell Biol. 82 2004 488 496
34. C. Prego, P. Paolicelli, B. Diaz, S. Vicente, A. Sanchez, A. Gonzalez-Fernandez, and M.J. Alonso Chitosan-based nanoparticles for improving immunization against hepatitis B infection Vaccine 28 2010 2607 2614
35. M. Rahman, S. Laurent, N. Tawil, L. Yahia, and M. Mahmoudi Protein-Nanoparticle Interactions 2013 Springer-Verlag
36. A.M. Saaf, J.M. Halbleib, X. Chen, S.T. Yuen, S.Y. Leung, W.J. Nelson, and P.O. Brown Parallels between global transcriptional programs of polarizing Caco-2 intestinal epithelial cells in vitro and gene expression programs in normal colon and colon cancer Mol. Biol. Cell 18 2007 4245 4260
37. R. Shaikh, T.R. Raj Singh, M.J. Garland, A.D. Woolfson, and R.F. Donnelly Mucoadhesive drug delivery systems Journal of pharmacy & bioallied sciences 3 2011 89 100
38. J. Sheng, L. Han, J. Qin, G. Ru, R. Li, L. Wu, D. Cui, P. Yang, Y. He, and J. Wang N-Trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption ACS Appl. Mater. Interfaces 7 2015 15430 15441
39. J. Singh, S. Pandit, V.W. Bramwell, and H.O. Alpar Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems Methods 38 2006 96 105
40. B. Speckmann, A. Pinto, M. Winter, I. Forster, H. Sies, and H. Steinbrenner Proinflammatory cytokines down-regulate intestinal selenoprotein P biosynthesis via NOS2 induction Free Radic. Biol. Med. 49 2010 777 785
41. M. Tafaghodi, V. Saluja, G.F. Kersten, H. Kraan, B. Slutter, J.P. Amorij, and W. Jiskoot Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics Vaccine 30 2012 5341 5348
42. D. Teijeiro-Osorio, C. Remunan-Lopez, and M.J. Alonso Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro Eur. J. Pharm. Biopharm. 71 2009 257 263
43. D. Vllasaliu, R. Exposito-Harris, A. Heras, L. Casettari, M. Garnett, L. Illum, and S. Stolnik Tight junction modulation by chitosan nanoparticles: Comparison with chitosan solution Int. J. Pharm. 400 2010 183 193
44. K.A. Woodrow, K.M. Bennett, and D.D. Lo Mucosal vaccine design and delivery Annu. Rev. Biomed. Eng. 14 2012 17 46
45. M. Zaitseva, T. Romantseva, K. Blinova, J. Beren, L. Sirota, D. Drane, and H. Golding Use of human MonoMac6 cells for development of in vitro assay predictive of adjuvant safety in vivo Vaccine 30 2012 4859 4865
46. L. Zhao, A. Seth, N. Wibowo, C.X. Zhao, N. Mitter, C. Yu, and A.P. Middelberg Nanoparticle vaccines Vaccine 32 2014 327 337
47. A. des Rieux, V. Fievez, M. Garinot, Y.J. Schneider, and V. Preat Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach Journal of Control. Release 116 2006 1 27